These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
281 related items for PubMed ID: 31398271
1. Targeting CDK9 for treatment of colorectal cancer. Rahaman MH, Lam F, Zhong L, Teo T, Adams J, Yu M, Milne RW, Pepper C, Lokman NA, Ricciardelli C, Oehler MK, Wang S. Mol Oncol; 2019 Oct; 13(10):2178-2193. PubMed ID: 31398271 [Abstract] [Full Text] [Related]
2. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Rahaman MH, Yu Y, Zhong L, Adams J, Lam F, Li P, Noll B, Milne R, Peng J, Wang S. Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564 [Abstract] [Full Text] [Related]
3. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Lam F, Abbas AY, Shao H, Teo T, Adams J, Li P, Bradshaw TD, Fischer PM, Walsby E, Pepper C, Chen Y, Ding J, Wang S. Oncotarget; 2014 Sep 15; 5(17):7691-704. PubMed ID: 25277198 [Abstract] [Full Text] [Related]
5. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells. Cao S, Yu Y, Chen S, Lei D, Wang S, Pan X, Peng J. Biochem Biophys Res Commun; 2017 Jan 22; 482(4):536-541. PubMed ID: 27847320 [Abstract] [Full Text] [Related]
7. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. Liu X, Shi S, Lam F, Pepper C, Fischer PM, Wang S. Int J Cancer; 2012 Mar 01; 130(5):1216-26. PubMed ID: 21484792 [Abstract] [Full Text] [Related]
9. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway. Yang L, Zhou F, Zhuang Y, Liu Y, Xu L, Zhao H, Xiang Y, Dai X, Liu Z, Huang X, Wang L, Zhao C. Br J Cancer; 2021 Feb 01; 124(3):645-657. PubMed ID: 33122847 [Abstract] [Full Text] [Related]
11. Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy. Zhang Z, Gao W, Zhou L, Chen Y, Qin S, Zhang L, Liu J, He Y, Lei Y, Chen HN, Han J, Zhou ZG, Nice EC, Li C, Huang C, Wei X. Theranostics; 2019 Feb 01; 9(17):4878-4892. PubMed ID: 31410188 [Abstract] [Full Text] [Related]
15. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity. Xu J, Li H, Wang X, Huang J, Li S, Liu C, Dong R, Zhu G, Duan C, Jiang F, Zhang Y, Zhu Y, Zhang T, Chen Y, Tang W, Lu T. Eur J Med Chem; 2020 Aug 15; 200():112424. PubMed ID: 32447197 [Abstract] [Full Text] [Related]
17. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF. Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210 [Abstract] [Full Text] [Related]
18. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice. Li X, Xia L, Ouyang X, Suyila Q, Su L, Su X. Protein Pept Lett; 2019 Feb 07; 26(7):512-522. PubMed ID: 30950338 [Abstract] [Full Text] [Related]